Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free GUD Stock Alerts

Knight Therapeutics (GUD) Competitors

Knight Therapeutics logo
C$7.55 0.00 (0.00%)
As of 04:22 PM Eastern
Compare

GUD vs. BHC, CRON, TLRY, THCX, and DHT.UN

Should you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Cronos Group (CRON), Tilray Brands (TLRY), Hydropothecary (THCX), and DRI Healthcare Trust (DHT.UN). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Knight Therapeutics has a consensus target price of C$6.50, indicating a potential downside of 13.91%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Bausch Health Companies has a beta of 0.588188, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of -0.214451, meaning that its stock price is 121% less volatile than the S&P 500.

In the previous week, Bausch Health Companies had 4 more articles in the media than Knight Therapeutics. MarketBeat recorded 4 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Bausch Health Companies' average media sentiment score of 0.22 beat Knight Therapeutics' score of 0.00 indicating that Bausch Health Companies is being referred to more favorably in the media.

Company Overall Sentiment
Bausch Health Companies Neutral
Knight Therapeutics Neutral

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$10.53B0.27-C$125.65M-C$3.24N/A
Knight TherapeuticsC$450.09M1.64-C$30.73M-C$0.05N/A

13.5% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 23.5% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Knight Therapeutics has a net margin of -1.19% compared to Bausch Health Companies' net margin of -13.54%. Bausch Health Companies' return on equity of 120.43% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-13.54% 120.43% 4.16%
Knight Therapeutics -1.19%-0.70%0.51%

Summary

Knight Therapeutics beats Bausch Health Companies on 9 of the 16 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Cronos Group (TSE:CRON) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Cronos Group has a beta of 1.036621, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of -0.214451, meaning that its stock price is 121% less volatile than the S&P 500.

In the previous week, Cronos Group had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for Cronos Group and 0 mentions for Knight Therapeutics. Cronos Group's average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score.

Company Overall Sentiment
Cronos Group Neutral
Knight Therapeutics Neutral

4.4% of Cronos Group shares are owned by institutional investors. Comparatively, 23.5% of Knight Therapeutics shares are owned by institutional investors. 46.4% of Cronos Group shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Knight Therapeutics has a net margin of -1.19% compared to Cronos Group's net margin of -6.37%. Knight Therapeutics' return on equity of -0.70% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos Group-6.37% -0.87% -3.73%
Knight Therapeutics -1.19%-0.70%0.51%

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$146.59M9.24-C$32.78M-C$0.02N/A
Knight TherapeuticsC$450.09M1.64-C$30.73M-C$0.05N/A

Cronos Group currently has a consensus target price of C$4.38, indicating a potential upside of 21.53%. Knight Therapeutics has a consensus target price of C$6.50, indicating a potential downside of 13.91%. Given Cronos Group's higher probable upside, equities analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cronos Group and Knight Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Knight Therapeutics compare to Tilray Brands?

Knight Therapeutics (TSE:GUD) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Knight Therapeutics has a beta of -0.214451, indicating that its share price is 121% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 3.243166, indicating that its share price is 224% more volatile than the S&P 500.

In the previous week, Tilray Brands had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for Tilray Brands and 0 mentions for Knight Therapeutics. Tilray Brands' average media sentiment score of 0.36 beat Knight Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company Overall Sentiment
Knight Therapeutics Neutral
Tilray Brands Neutral

23.5% of Knight Therapeutics shares are held by institutional investors. Comparatively, 4.1% of Tilray Brands shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Comparatively, 0.7% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Knight Therapeutics has a net margin of -1.19% compared to Tilray Brands' net margin of -158.75%. Knight Therapeutics' return on equity of -0.70% beat Tilray Brands' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics-1.19% -0.70% 0.51%
Tilray Brands -158.75%-88.06%-1.41%

Knight Therapeutics has higher earnings, but lower revenue than Tilray Brands. Knight Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$450.09M1.64-C$30.73M-C$0.05N/A
Tilray BrandsC$858.28M1.09-C$183.24M-C$14.63N/A

Knight Therapeutics presently has a consensus target price of C$6.50, suggesting a potential downside of 13.91%. Tilray Brands has a consensus target price of C$13.30, suggesting a potential upside of 70.51%. Given Tilray Brands' higher probable upside, analysts plainly believe Tilray Brands is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Tilray Brands
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Knight Therapeutics beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does Knight Therapeutics compare to Hydropothecary?

Knight Therapeutics (TSE:GUD) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company Overall Sentiment
Knight Therapeutics Neutral
Hydropothecary Neutral

Hydropothecary has lower revenue, but higher earnings than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$450.09M1.64-C$30.73M-C$0.05N/A
HydropothecaryN/AN/AN/AN/AN/A

Hydropothecary has a net margin of 0.00% compared to Knight Therapeutics' net margin of -1.19%. Hydropothecary's return on equity of 0.00% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics-1.19% -0.70% 0.51%
Hydropothecary N/A N/A N/A

Knight Therapeutics presently has a consensus target price of C$6.50, suggesting a potential downside of 13.91%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Hydropothecary.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hydropothecary
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

23.5% of Knight Therapeutics shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Knight Therapeutics beats Hydropothecary on 7 of the 9 factors compared between the two stocks.

How does Knight Therapeutics compare to DRI Healthcare Trust?

DRI Healthcare Trust (TSE:DHT.UN) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, media sentiment, earnings and valuation.

In the previous week, DRI Healthcare Trust had 3 more articles in the media than Knight Therapeutics. MarketBeat recorded 3 mentions for DRI Healthcare Trust and 0 mentions for Knight Therapeutics. DRI Healthcare Trust's average media sentiment score of 0.85 beat Knight Therapeutics' score of 0.00 indicating that DRI Healthcare Trust is being referred to more favorably in the media.

Company Overall Sentiment
DRI Healthcare Trust Positive
Knight Therapeutics Neutral

DRI Healthcare Trust has higher earnings, but lower revenue than Knight Therapeutics. Knight Therapeutics is trading at a lower price-to-earnings ratio than DRI Healthcare Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DRI Healthcare TrustC$153.37M5.80C$9.73M-C$0.91N/A
Knight TherapeuticsC$450.09M1.64-C$30.73M-C$0.05N/A

DRI Healthcare Trust has a beta of 0.347429, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of -0.214451, meaning that its stock price is 121% less volatile than the S&P 500.

DRI Healthcare Trust has a net margin of 5.02% compared to Knight Therapeutics' net margin of -1.19%. DRI Healthcare Trust's return on equity of 2.06% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
DRI Healthcare Trust5.02% 2.06% 4.22%
Knight Therapeutics -1.19%-0.70%0.51%

DRI Healthcare Trust presently has a consensus target price of C$18.88, indicating a potential upside of 16.80%. Knight Therapeutics has a consensus target price of C$6.50, indicating a potential downside of 13.91%. Given DRI Healthcare Trust's higher possible upside, research analysts plainly believe DRI Healthcare Trust is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DRI Healthcare Trust
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

0.6% of DRI Healthcare Trust shares are owned by institutional investors. Comparatively, 23.5% of Knight Therapeutics shares are owned by institutional investors. 0.1% of DRI Healthcare Trust shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

DRI Healthcare Trust beats Knight Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUD vs. The Competition

Export
MetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE Exchange
Market CapC$740.32MC$1.63BC$6.25BC$11.72B
Dividend YieldN/A2.97%2.73%6.22%
P/E Ratio-151.004.1829.0423.83
Price / Sales1.641,488.53476.4813.46
Price / Cash3.8510.3727.6282.69
Price / Book0.9810.729.674.48
Net Income-C$30.73MC$21.15BC$3.55BC$300.68M
7 Day Performance2.30%-1.16%1.70%0.12%
1 Month Performance1.34%0.17%5.62%2.88%
1 Year Performance24.18%24.19%34.42%57.78%

Knight Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUD
Knight Therapeutics
N/AC$7.55
flat		C$6.50
-13.9%		N/AC$740.32MC$450.09MN/A725
BHC
Bausch Health Companies
0.5813 of 5 stars		C$7.66
-1.4%		N/AN/AC$2.90BC$10.27B18.2419,900
CRON
Cronos Group
1.8155 of 5 stars		C$3.52
-2.8%		C$4.38
+24.3%		N/AC$1.36BC$146.59MN/A450
TLRY
Tilray Brands
1.688 of 5 stars		C$8.43
-5.9%		C$13.30
+57.8%		N/AC$1.01BC$858.28MN/A2,650
THCX
Hydropothecary
N/AC$5.30
+6.6%		N/AN/AC$949.11MN/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel